Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MET | P08581 | 14/20 | 0.61 |
| ▸ | POLB | P06746 | 1/20 | 0.53 |
| ▸ | AXL | P30530 | 1/20 | 0.47 |
| ▸ | MEN1 | O00255 | 2/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.45 |
| ▸ | LMNA | P02545 | 1/20 | 0.45 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.45 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.43 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.43 |
| ▸ | KDR | P35968 | 2/20 | 0.43 |
| ▸ | MAPT | P10636 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4831929 | 0.90 | MET (0.63) | METAXLKMT2ALMNASMN1; SMN2 | |
| SCHEMBL4335164 | 0.84 | POLB (0.51) | METPOLBAXLTDP1KDR | |
| SCHEMBL3558819 | 0.82 | MET (0.64) | METPOLBAXLSMN1; SMN2KDR | |
| SCHEMBL1137330 | 0.80 | MET (0.73) | METAXLKDR | |
| SCHEMBL4333424 | 0.80 | MET (0.86) | METKDR | |
| SCHEMBL4831742 | 0.80 | MET (0.64) | MET | |
| SCHEMBL372306 | 0.80 | POLB (0.64) | POLBMEN1KMT2ALMNATDP1 | |
| SCHEMBL4838514 | 0.79 | MET (0.56) | METPOLBAXLKMT2ALMNA | |
| SCHEMBL4322880 | 0.79 | MET (0.47) | METPOLBAXLKMT2ALMNA | |
| SCHEMBL1136952 | 0.79 | MET (0.82) | METAXLKDR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7470693-B2 | Oxalamide derivatives as kinase inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2008-12-30 | — | — | US | claimed |
| US-20060241104-A1 | Oxalamide derivatives as kinase inhibitors | BRISTOL-MYERS SQUIBB COMPANY | 2006-10-26 | — | — | US | claimed |
| US-7470693-B2 | Oxalamide derivatives as kinase inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2008-12-30 | — | — | US | disclosed |
| US-7470693-B2 | Oxalamide derivatives as kinase inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2008-12-30 | — | — | US | disclosed |
| US-7470693-B2 | Oxalamide derivatives as kinase inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2008-12-30 | — | — | US | disclosed |
| US-20060241104-A1 | Oxalamide derivatives as kinase inhibitors | BRISTOL-MYERS SQUIBB COMPANY | 2006-10-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060241104-A1 | Oxalamide derivatives as kinase inhibitors | PDK1, OAT, PDXK | MET 337/4885POLB 459/4885AXL 1110/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.